Greg Harrison
Stock Analyst at B of A Securities
(4.48)
# 269
Out of 5,182 analysts
106
Total ratings
56.79%
Success rate
20.9%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintains: Buy | $44 → $41 | $24.80 | +65.32% | 10 | Apr 21, 2026 | |
| UTHR United Therapeutics | Maintains: Neutral | $569 → $626 | $569.11 | +10.00% | 6 | Mar 31, 2026 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $46 → $51 | $25.89 | +96.99% | 3 | Mar 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $495 → $558 | $430.14 | +29.73% | 8 | Feb 13, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $36 → $30 | $13.20 | +127.27% | 3 | Oct 27, 2025 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $40.89 | -24.19% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $9.32 | +114.59% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $69.71 | -18.23% | 7 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $302.11 | +48.95% | 6 | Aug 1, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $0.34 | +3,089.33% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $32 → $35 | $8.87 | +294.59% | 2 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $37.11 | +48.21% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $51 → $19 | $3.43 | +453.94% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $37.65 | -1.73% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $11.37 | +128.67% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $40.99 | -51.21% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.51 | -0.66% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $30.56 | +30.89% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $67.26 | +11.51% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $13.47 | +33.63% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $33.33 | -64.00% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.20 | +646.27% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $3.06 | +390.20% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $14.67 | -79.55% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.96 | +7,227.54% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $14.65 | +268.60% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $83.81 | +7.39% | 5 | Mar 14, 2022 |
Agios Pharmaceuticals
Apr 21, 2026
Maintains: Buy
Price Target: $44 → $41
Current: $24.80
Upside: +65.32%
United Therapeutics
Mar 31, 2026
Maintains: Neutral
Price Target: $569 → $626
Current: $569.11
Upside: +10.00%
Mineralys Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $46 → $51
Current: $25.89
Upside: +96.99%
Vertex Pharmaceuticals
Feb 13, 2026
Maintains: Sector Perform
Price Target: $495 → $558
Current: $430.14
Upside: +29.73%
Intellia Therapeutics
Oct 27, 2025
Maintains: Buy
Price Target: $36 → $30
Current: $13.20
Upside: +127.27%
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $40.89
Upside: -24.19%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $9.32
Upside: +114.59%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $69.71
Upside: -18.23%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $302.11
Upside: +48.95%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $0.34
Upside: +3,089.33%
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $8.87
Upside: +294.59%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $37.11
Upside: +48.21%
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $3.43
Upside: +453.94%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $37.65
Upside: -1.73%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $11.37
Upside: +128.67%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $40.99
Upside: -51.21%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.51
Upside: -0.66%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $30.56
Upside: +30.89%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $67.26
Upside: +11.51%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $13.47
Upside: +33.63%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $33.33
Upside: -64.00%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.20
Upside: +646.27%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $3.06
Upside: +390.20%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $14.67
Upside: -79.55%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $0.96
Upside: +7,227.54%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $14.65
Upside: +268.60%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $83.81
Upside: +7.39%